XOMA Royalty Corporation (XOMA)
(Delayed Data from NSDQ)
$26.16 USD
-0.30 (-1.13%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $26.03 -0.13 (-0.50%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$26.16 USD
-0.30 (-1.13%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $26.03 -0.13 (-0.50%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Zacks News
XOMA Royalty (XOMA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
XOMA Royalty (XOMA) delivered earnings and revenue surprises of -7.69% and 32.45%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
TELA Bio (TELA) delivered earnings and revenue surprises of -13.33% and 15.31%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
ITeos Therapeutics, Inc. (ITOS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
iTeos Therapeutics (ITOS) delivered earnings and revenue surprises of 82.69% and 733.33%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
MaxCyte, Inc. (MXCT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
MaxCyte (MXCT) delivered earnings and revenue surprises of 35.71% and 27.18%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Xoma (XOMA) Surges 6.4%: Is This an Indication of Further Gains?
by Zacks Equity Research
Xoma (XOMA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Xoma (XOMA) Soars 15.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Xoma (XOMA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Certara, Inc. (CERT) Q1 Earnings Meet Estimates
by Zacks Equity Research
Certara (CERT) delivered earnings and revenue surprises of 0% and 2.30%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Xoma (XOMA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Lexicon (LXRX) delivered earnings and revenue surprises of -11.11% and 3.09%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Xoma (XOMA) Moves 7.7% Higher: Will This Strength Last?
by Zacks Equity Research
Xoma (XOMA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of 30.69% and 15.25%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Vertex (VRTX): Can Its 5.0% Jump Turn into More Strength?
by Zacks Equity Research
Vertex (VRTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Xoma (XOMA) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Xoma (XOMA) delivered earnings and revenue surprises of -140% and 95.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Xoma (XOMA) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Xoma (XOMA) delivered earnings and revenue surprises of -381.82% and 88.42%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Xoma (XOMA) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Xoma (XOMA) delivered earnings and revenue surprises of 5.88% and 12.73%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of -5.97% and 44.58%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Xoma (XOMA) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Xoma (XOMA) delivered earnings and revenue surprises of -466.67% and -85.22%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Xoma (XOMA) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in Xoma (XOMA): Can Its 11.2% Jump Turn into More Strength?
by Zacks Equity Research
Xoma (XOMA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Xoma (XOMA) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Xoma (XOMA) delivered earnings and revenue surprises of 24.39% and -56.89%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Xoma (XOMA) Q2 Earnings Expected to Decline
by Zacks Equity Research
Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Xoma (XOMA) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Xoma (XOMA) delivered earnings and revenue surprises of -366.67% and -69.39%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Xoma (XOMA) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Xoma (XOMA) delivered earnings and revenue surprises of 2.33% and 126.07%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Xoma (XOMA) to Report Q4 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
XOMA Catches Eye: Stock Jumps 7.9%
by Zacks Equity Research
XOMA saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.